JP2013534248A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534248A5
JP2013534248A5 JP2013524925A JP2013524925A JP2013534248A5 JP 2013534248 A5 JP2013534248 A5 JP 2013534248A5 JP 2013524925 A JP2013524925 A JP 2013524925A JP 2013524925 A JP2013524925 A JP 2013524925A JP 2013534248 A5 JP2013534248 A5 JP 2013534248A5
Authority
JP
Japan
Prior art keywords
compound
butyl
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013524925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/047901 external-priority patent/WO2012024284A1/en
Publication of JP2013534248A publication Critical patent/JP2013534248A/ja
Publication of JP2013534248A5 publication Critical patent/JP2013534248A5/ja
Pending legal-status Critical Current

Links

JP2013524925A 2010-08-17 2011-08-16 脂質付加された免疫反応調節化合物の組成物、製剤及び方法 Pending JP2013534248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37451210P 2010-08-17 2010-08-17
US61/374,512 2010-08-17
PCT/US2011/047901 WO2012024284A1 (en) 2010-08-17 2011-08-16 Lipidated immune response modifier compound compositions, formulations, and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015221889A Division JP6360026B2 (ja) 2010-08-17 2015-11-12 脂質付加された免疫反応調節化合物の組成物、製剤及び方法

Publications (2)

Publication Number Publication Date
JP2013534248A JP2013534248A (ja) 2013-09-02
JP2013534248A5 true JP2013534248A5 (OSRAM) 2014-10-02

Family

ID=45605411

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013524925A Pending JP2013534248A (ja) 2010-08-17 2011-08-16 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2015221889A Active JP6360026B2 (ja) 2010-08-17 2015-11-12 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2017019604A Active JP6392916B2 (ja) 2010-08-17 2017-02-06 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2018150491A Active JP6710727B2 (ja) 2010-08-17 2018-08-09 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2020090879A Active JP7104096B2 (ja) 2010-08-17 2020-05-25 脂質付加された免疫反応調節化合物の組成物、製剤及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015221889A Active JP6360026B2 (ja) 2010-08-17 2015-11-12 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2017019604A Active JP6392916B2 (ja) 2010-08-17 2017-02-06 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2018150491A Active JP6710727B2 (ja) 2010-08-17 2018-08-09 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP2020090879A Active JP7104096B2 (ja) 2010-08-17 2020-05-25 脂質付加された免疫反応調節化合物の組成物、製剤及び方法

Country Status (20)

Country Link
US (9) US9242980B2 (OSRAM)
EP (2) EP2606047B1 (OSRAM)
JP (5) JP2013534248A (OSRAM)
CN (2) CN103097386A (OSRAM)
AU (1) AU2011292146B2 (OSRAM)
BR (1) BR112013003772A2 (OSRAM)
CA (2) CA2808624C (OSRAM)
CY (1) CY1118815T1 (OSRAM)
DK (1) DK2606047T3 (OSRAM)
ES (2) ES2617451T3 (OSRAM)
HR (1) HRP20170433T1 (OSRAM)
HU (1) HUE033901T2 (OSRAM)
LT (1) LT2606047T (OSRAM)
MX (1) MX359517B (OSRAM)
PL (1) PL2606047T3 (OSRAM)
PT (1) PT2606047T (OSRAM)
RS (1) RS55819B1 (OSRAM)
SI (1) SI2606047T1 (OSRAM)
SM (1) SMT201700182T1 (OSRAM)
WO (1) WO2012024284A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170433T1 (hr) 2010-08-17 2017-05-05 3M Innovative Properties Company Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CR20160214A (es) * 2013-11-05 2016-10-11 3M Innovative Properties Co Formulaciones de inyección con base en aceite de sésamo
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
CN105268386B (zh) 2014-06-03 2021-03-12 传感器电子技术股份有限公司 紫外透明外壳
WO2016019232A1 (en) * 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2017004421A1 (en) * 2015-06-30 2017-01-05 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
CN107922416B (zh) 2015-08-31 2021-07-02 3M创新有限公司 含有取代的胍基团的咪唑并[4,5-c]环化合物
EP3344622B1 (en) 2015-08-31 2021-07-07 3M Innovative Properties Company Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
EP3355933B1 (en) 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN108290845B (zh) 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
WO2017102652A1 (en) * 2015-12-14 2017-06-22 Glaxosmithkline Biologicals S.A. Pegylated imidazoquinolines as tlr7 and tlr8 agonists
HUE059605T2 (hu) * 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
AU2017268175B2 (en) 2016-05-16 2023-02-23 Access To Advanced Health Institute PEGylated liposomes and methods of use
TW201840316A (zh) * 2017-01-12 2018-11-16 美商麥迪紐有限責任公司 Ｔｏｌｌ樣受體７／８激動劑之安全性和藥物活性
US10766896B2 (en) 2017-03-01 2020-09-08 3M Innovative Properties Company Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
US11032816B2 (en) * 2017-08-10 2021-06-08 Qualcomm Incorporated Techniques and apparatuses for variable timing adjustment granularity
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CA3092545A1 (en) 2018-02-28 2019-09-06 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
EP3802536B1 (en) 2018-05-24 2022-07-13 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
MX2021000951A (es) 2018-07-23 2021-06-23 Sumitomo Pharma Co Ltd Composición que contiene vacuna contra la influenza.
JP7538803B6 (ja) * 2019-02-01 2024-09-10 ユー，ニンフイ イミダゾキノリンアミン誘導体、医薬組成物、その使用
AU2020407871A1 (en) * 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
EP4578448A4 (en) * 2023-06-01 2025-10-15 United Immunity Co Ltd COMPLEX
WO2024248117A1 (ja) * 2023-06-01 2024-12-05 ユナイテッド・イミュニティ株式会社 複合体
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ATE121088T1 (de) 1990-10-05 1995-04-15 Minnesota Mining & Mfg Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP0780368B1 (de) 1995-12-21 1999-07-21 Akzo Nobel N.V. Verfahren zur Herstellung von Thioglykolsäure
JPH09176116A (ja) 1995-12-27 1997-07-08 Toray Ind Inc 複素環誘導体およびその医薬用途
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
CZ294563B6 (cs) 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
JPH114764A (ja) 1997-06-17 1999-01-12 Mitsubishi Electric Corp 電気湯沸器
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
AU2006216669A1 (en) 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
KR100455713B1 (ko) 2001-01-29 2004-11-06 호남석유화학 주식회사 올레핀 중합용 다중핵 메탈로센 촉매 및 이를 이용한중합방법
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (ja) 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
AU2002343728A1 (en) 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1450804B9 (en) 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1478327B1 (en) 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
AU2003216851B2 (en) 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2488801A1 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
ES2271650T3 (es) 2002-07-23 2007-04-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Preparacion de 1h-imidazo (4,5-c) quinolin-4-aminas mediante los productos intermedios de 1h-imidazo (4,5-c) quinolin-4-ftalimida.
DE60312701T8 (de) 2002-07-26 2008-08-21 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Darstellung von 1h-imidazo[4,5-c]chinolin-4-aminen über neue 1h-imidazo[4,5-c] chinolin-4-cyano- und 1h-imidazo[4,5-c]chinolin-4-carboxamid intermediate
DK1545597T3 (da) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004075865A2 (en) 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
CA2517528A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006523212A (ja) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
CA2518282C (en) 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1615665A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040214851A1 (en) 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004110992A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
US6943255B2 (en) 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
US20050106300A1 (en) 2003-06-30 2005-05-19 Purdue Research Foundation Method for producing a material having an increased solubility in alcohol
AU2004261243A1 (en) 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
AU2004264336B2 (en) 2003-08-05 2010-12-23 3M Innovative Properties Company Formulations containing an immune response modifier
AU2004266641A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005018555A2 (en) * 2003-08-14 2005-03-03 3M Innovative Properties Company Lipid-modified immune response modifiers
ES2545826T3 (es) * 2003-08-14 2015-09-16 3M Innovative Properties Company Modificadores de la respuesta inmune modificados con lípidos
CA2551075A1 (en) 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
CA2536249A1 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
MXPA06002408A (es) 2003-09-02 2006-06-20 3M Innovative Properties Co Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1664342A4 (en) 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
EP1668010A2 (en) 2003-10-01 2006-06-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
JP2007509987A (ja) 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
ITMI20032121A1 (it) 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
CA2547085A1 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
CA2549216A1 (en) 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
EP1699792A1 (en) 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050239735A1 (en) 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US20050158325A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005089317A2 (en) 2004-03-15 2005-09-29 3M Innovative Properties Company Immune response modifier formulations and methods
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
JP2008505857A (ja) 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー 粘膜ワクチン接種のための組成物および方法
WO2005123079A2 (en) 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259907A1 (en) 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US20060045886A1 (en) 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
US20060045885A1 (en) 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
US20090270443A1 (en) 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006028451A1 (en) 2004-09-03 2006-03-16 3M Innovative Properties Company 1-amino 1-h-imidazoquinolines
EP1632564A1 (en) * 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Vaccine against severe accute respiratory syndrome causing coronavirus (SARS-CoV)
US20080193468A1 (en) 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
BRPI0515316A (pt) 2004-09-14 2008-07-15 Chiron Corp compostos de imidazoquinolina
US20070243215A1 (en) 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
EP1819226A4 (en) 2004-12-08 2010-12-29 3M Innovative Properties Co COMBINATIONS AND METHODS OF IMMUNOSTIMULATION
EP1819364A4 (en) 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8461174B2 (en) 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP2008526752A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物の多経路投与
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
NZ556399A (en) 2004-12-30 2009-03-31 Takeda Pharmaceutical 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
ATE545010T1 (de) 2005-02-02 2012-02-15 Mocon Inc Instrument und verfahren zum detektieren und melden der grösse von lecks in hermetisch abgedichteten verpackungen
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
WO2006086449A2 (en) 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1845986A2 (en) 2005-02-11 2007-10-24 Coley Pharmaceutical Group, Inc. Substituted fused [1,2]imidazo[4,5-c]ring compounds and methods
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006098852A2 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006223148A1 (en) 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863813A2 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
JP2008535831A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレーテッド 環閉鎖および関連する方法および中間体
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (ja) 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
BRPI0615250A2 (pt) 2005-09-02 2011-05-10 Pfizer 1h-imidazopiridinas substituÍdas por hidràxi, composiÇço farmacÊutica contendo as mesmas, bem como seus usos
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20090240055A1 (en) 2005-09-23 2009-09-24 Krepski Larry R Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007079203A2 (en) 2005-12-28 2007-07-12 3M Innovative Properties Company Treatment for cutaneous t cell lymphoma
WO2007092641A2 (en) 2006-02-10 2007-08-16 Coley Pharmaceutical Group, Inc. Method for substituted 1h-imidazo[4,5-c]pyridines
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2007149802A2 (en) 2006-06-19 2007-12-27 3M Innovative Properties Company Formulation for delivery of immune response modifiers
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8124096B2 (en) 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
HRP20170433T1 (hr) 2010-08-17 2017-05-05 3M Innovative Properties Company Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2012167081A1 (en) * 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom

Similar Documents

Publication Publication Date Title
JP2013534248A5 (OSRAM)
JP2013519645A5 (OSRAM)
JP2013542247A5 (OSRAM)
JP2012532874A5 (OSRAM)
JP2014515013A5 (OSRAM)
JP2012255026A5 (OSRAM)
JP2014500861A5 (OSRAM)
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
JP2015512931A5 (OSRAM)
JP2010270124A5 (OSRAM)
JP2013518107A5 (OSRAM)
JP2013510120A5 (OSRAM)
JP2018021051A5 (OSRAM)
JP2014521735A5 (OSRAM)
JP2015155440A5 (OSRAM)
JP2013508279A5 (OSRAM)
JP2017531038A5 (OSRAM)
JP2013509429A5 (OSRAM)
JP2013525444A5 (OSRAM)
JP2013537423A5 (OSRAM)
JP2011246469A5 (OSRAM)
JP2016516074A5 (OSRAM)
JP2014516033A5 (OSRAM)
JP2012523395A5 (OSRAM)
JP2011046708A5 (OSRAM)